Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 501 - 550 out of 6,182

Document Document Title
WO/2006/122782A1
N-(2-hydroxyalkanoyl) -N, N' -dialkylureas of general formula (I) are described A-X-(A)n, where A: m = 0 or m = 1; when m = 0, X = R''', where R''' is an aliphatic, cycloaliphatic, arylaliphatic radical, C1-C18; when m = 1, X = -(CH2)n-,...  
WO/2006/122772A1
The invention relates to salts of substituted allophanates, to methods for producing them, to drugs containing said compounds and to the use of said compounds for producing drugs.  
WO/2006/122072A2
The present invention relates to processes for preparing biaryl ureas derivatives and analogs thereof. The invention also provides compounds useful as intermediates in the processes of the present invention. The process is useful for pre...  
WO2006083924A8
1-Acylamino-2-hydroxy-3-amino-?-arylalkanes of formula I. and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.  
WO/2006/117549A1
Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intr...  
WO/2006/118071A1
In an apparatus for synthesizing urea and a method of improving the same, it becomes possible to provide a heavy condenser at a relatively low position and, further, it becomes possible to overcome the problems caused by passing a proces...  
WO/2006/118070A1
In an apparatus for synthesizing urea, it is avoided to pass downward a urea synthesis solution, which is a two-phase gas-liquid stream, and the stream is stabilized as such (i.e., as being the two-phase gas-liquid stream) to enable smoo...  
WO/2006/108712A1
The invention relates to poly-substituted tetrahydronaphtalene derivatives of formula (I) and to a method for the production and the use thereof in the form of antiphlogistics.  
WO/2006/101318A1
This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1 )antagonist; and a pharmaceutical composition containing the same. The...  
WO/2006/101321A1
This present invention relates to novel compounds, isomer thereof or pharmaceutically acceptable salts thereof as vanilloid receptor (Vanilloid Receotor 1; VR1; TRPV1) antagonist; and a pharmaceutical composition containing the same. The...  
WO/2006/100563A1
Methods and reagents for transition metal-promoted carbonylation via isocyanate using carbon-isotope labeled carbon monoxide are provided. The resultant carbon-isotope labeled compounds are useful as radiopharmaceuticals, especially for ...  
WO/2006/092204A1
The invention relates to a new class of compounds with action inhibiting carnitine palmitoyl transferase (CPT), pharmaceutical compounds which contain at least one new compound according to the invention, and their therapeutic use in the...  
WO2006074025B1
Compounds of formula (I) : wherein, Z is -N-or>CH; R1 is -H or -C1-4alkyl; Ar1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring mem...  
WO/2006/089952A1
The invention relates to novel compounds of the formula (I) and their use in stabilization of Factor Vila or other Factor VII polypeptides, particularly in aqueous liquid compositions thereof.  
WO2005107762A3
Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of one or more mitotic kinesins are disclosed.  
WO/2006/084688A1
Compounds of the formula (I): Wherein R1, R2, X and N are as defined in the specification; E is N, CH; A1 and A" are terminal groups as defined in the specification. The compounds have utility as HIV-I protease inhibitors.  
WO/2006/083924A1
1-Acylamino-2-hydroxy-3-amino-&ohgr -arylalkanes of formula I. and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive, medicinally active ingredients.  
WO/2006/083266A1
In accordance with the present invention, compounds having formula (I), where the variables are as identified in the claims, that inhibit Type III protein secretion have been identified, and methods for their use provided. In one aspect ...  
WO/2006/074025A1
Compounds of formula (I) : wherein, Z is -N-or>CH; R1 is -H or -C1-4alkyl; Ar1 is 2-thiazolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-primidinyl, 5-pyrimidinyl, or phenyl, each unsubstituted or substituted at a carbon ring mem...  
WO/2006/069690A1
The invention relates to radiation-hardenable compounds, methods for the production thereof and the use thereof, in addition to highly scratch-resistant coating materials containing said compounds.  
WO/2006/063653A1
The invention relates to a method for producing onium salts with tetrafluoroborate anion by reacting an onium halide with an oxonium tetrafluoroborate, sulfonium tetrafluoroborate, or triphenylcarbonium tetrafluoroborate.  
WO/2006/063654A1
The invention relates to a method for producing onium alkyl sulfates by reacting an onium halogenide with a symmetrically substituted dialkyl sulfate, the alkyl group thereof containing between 1 and 14 C atoms, with an unsymmetrically s...  
WO/2006/062580A1
The invention relates to novel compounds and processes for their preparation and their use for preparing medicaments for the treatment of disorders, especially hyper-proliferative disorders.  
WO2006004613A3
The invention relates to pharmaceutically acceptable salts of guanylhydrazone-containing compounds, for example, Semapimod. The invention also relates to pharmaceutically acceptable compositions comprising the salts and methods for their...  
WO/2006/052722A1
The invention relates to glycogen phosphorylase inhibitor compounds, pharmaceutical compositions of these compounds, methods of treatment using the pharmaceutical compositions to treat diabetes, conditions associated with diabetes, and/o...  
WO/2006/050800A1
Compounds of formula (I), where R6, R7, R8, R9, Het1, X and X' have the meanings given in claim 1 are tyrosine kinase inhibitors, in particular, of TIE-2, and Raf kinases and can be used, amongst other things, for the treatment of tumours.  
WO/2006/049264A1
There are provided a novel ethylenically unsaturated group-containing isocyanate compound, a process for producing the same, and a reactive monomer produced from the isocyanate compound, a reactive polymer and its use. The ethylenically ...  
WO/2006/041841A1
Novel phenyl compounds, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the compounds are agonists and/or ligands of cannabinoid receptors and may be...  
WO/2006/040625A1
The present invention relates to novel compounds useful as dipeptidyl peptidase IV (DPP-IV) inhibitors of the formula: (I) wherein Y is -S(O)m, -CH2-, CHF, or -CF2; m is 0, 1, or 2; X is a bond, C1-C5 alkyl (e.g., -CH2-), or -C(=0)-; the...  
WO/2006/037468A1
Compounds of Formula (I) are HIV reverse transcriptase inhibitors, wherein T is O or S; U is O, S, N(R4), or a direct bond linking V to the C(=T) moiety; V is optionally substituted C1-6 alkylene; W is C(O)N(R5) or a direct bond linking ...  
WO/2006/038606A1
Disclosed are a compound represented by the formula (I) below, a pharmaceutically acceptable salt thereof, a solvate of those, and a pharmaceutical composition containing such a compound. (In the formula, X1 represents N or CR2; X2 repre...  
WO2005007621A3
This invention describes compounds useful as ubiquitin ligase inhibitors. The compounds of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved. The invention also provides f...  
WO/2006/037574A1
The present invention is concerned with an improved method of producing (R)-2-acetamido-N-benzyl-3-methoxypropionamide (lacosamide) comprising the 0-methylation of a compound of formula (I) to produce a compound of formula (I I) in a sin...  
WO2004089296A3
Inhibitors of the soluble epoxide hydrolase (sEH) are provided that incorporate multiple pharmacophores and are useful in the treatment of diseases.  
WO2005122379A9
The present invention provides a 4ß1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unna...  
WO/2006/023457A1
This invention provides compounds of formula I wherein R1, R2, R3, R4, R5, R6, R7, R8a, R8b, W, a and b are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this ...  
WO/2006/018326A1
The invention relates to novel biaromatic compounds that correspond to the general formula (I) and also to the method for preparing them, and to their use in pharmaceutical compositions for use in human or veterinary medicine (in dermato...  
WO/2006/015852A1
Compounds of formula (I) in free or salt form, wherein T, X, R1, R2, Ra, R3, R4, R5 and U have the meanings as indicated in the specification, are useful for treating a condition mediated by CCR-3, particularly an inflammatory or allergi...  
WO2004101752A3
Novel acyl urea, carbamate, thiocarbamate and related compounds are provided which are effective in inhibiting the cytokine-mediated inflammatory response in cultured cells, in ameliorating bone destruction in an animal model of arthriti...  
WO2005058798A3  
WO/2006/017216A1
This invention relates to hydroxamic acid derivatives having a urea linkage, that are inhibitors of histone deacetylase (HDAC), and are useful in the prevention and/or treatment of cellular proliferative diseases, for example cancer, aut...  
WO/2006/010362A1
The invention relates to 1-amino adamantane derivatives and 3-amino adamantane-1-carboxylic acid derivatives, wherein the 5th and/or 7th position of the adamantane base frame can be substituted in any particular manner. The invention als...  
WO/2006/011420A1
Disclosed is a compound represented by the general formula (1) below. (1) [In the formula, R represents a hydrogen atom or a lower alkyl group; X represents a sulfur atom or an oxygen atom; Y represents a chain, branched or cyclic alkyl ...  
WO2005113511A9
The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods fo...  
WO/2006/006725A1
The present invention provides a reversible thermosensitive recording medium including a support and a thermosensitive recording layer thereon, in which the thermosensitive recording layer comprises an electron-donating coloring compound...  
WO/2006/003923A1
Disclosed is an excellent LXR modulator. Specifically disclosed are compounds represented by the following general formula (I). (In the formula, R1 represents -COR9 (wherein R9 represents an alkyl, an optionally substituted alkoxy or an ...  
WO/2006/002474A1
Benzoyl urea derivatives that are alpha helical peptide mimetics that mimic BH3-only proteins, compositions containing them, their conjugation to cell-targeting moieties, and their use in the regulation of cell death are disclosed. The b...  
WO/2005/123666A1
The invention relates to compounds of formula (I), wherein R e R1, R2, X and n are as defined in the description, and their use for the preparation of pharmaceutical compositions for the treatment of inflammatory states.  
WO2004098512A3
The present application describes modulators of MCP 1 of formula (I) or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma, multiple sclerosis, artherosclerosis, and rheumatoid arthritis.  
WO/2005/122379A2
The present invention provides a 4ß1 integrin ligands that display high binding affinity, specificity, and stability. The ligands comprise a peptide having n independently selected amino acids, wherein at least one amino acid is an unna...  

Matches 501 - 550 out of 6,182